What is your current role in EPAD? I am a project manager for the overall EPAD project. My main role, as member of the EPAD Project Management office (WP5), is to provide overall management to the project including supporting the coordinator in liaising with the Innovative Medicines Initiative (IMI), follow up and management of the…
DetailsWhat is your current role in EPAD? I was the local EPAD Principal Investigator but my neurology colleague Tobias Langheinrich has recently taken over. Greater Manchester is one of the EPAD sites. The Greater Manchester Dementia Research Centre (GMDRC) is a collaboration between the NIHR, Greater Manchester Mental Health Foundation Trust and the University of…
DetailsAs part of the Clinical Trials Digital Week, KNect365 Life Sciences organised a global 4-day series of live educational webcasts and downloadable resources providing the latest insights into clinical partnerships, outsourcing, operations and technology from 13-16 May 2019. Katrin Haeverans (Clinical Scientist and External Affairs Director at Janssen) was invited to deliver a webinar on…
DetailsThe European Prevention of Alzheimer’s Dementia (EPAD) project, a highly innovative programme aiming to streamline the testing and development of preventative treatments for Alzheimer’s disease, is very pleased to announce the upcoming release of its first wave of data including the baseline data from the first 500 research participants (V500.0). Researchers will now have access…
DetailsNeuronet, a coordination and support action funded by the Innovative Medicines Initiative (IMI), brings together 15 IMI consortium projects working on neurodegenerative disease (such as Alzheimer’s), encompassing over EUR 290 million in research funding. The Neuronet programme held four parallel sessions as part of the Alzheimer Europe conference on 24 and 25 October. This involved…
DetailsLynne Hughes, VP and head of medical CNS strategy at IQVIA, talked about EPAD accomplishments and challenges in an interview article. She provided insights on how EPAD and IQVIA are contributing to advance Alzheimer’s disease research. EPAD is celebrating five years since its inception. What has it accomplished? We have 23 European sites enrolling subjects…
DetailsThe EPAD project, originally scheduled to end in December 2019, has been extended. We are pleased to share that IMI has officially approved our request for a 6-month no-cost extension to the project, setting the end date in June 2020. This extension will allow the delivery of the start of the first EPAD Proof of…
DetailsThe Neuronet (Efficiently Networking European Neurodegeneration Research) communication team is proud to announce the launch of the official project website: http://imi-neuronet.org/ Neuronet is a three-year coordination and support action that kicked off in March 2019. The aim of Neuronet is to set up an efficient platform to boost collaboration across research projects focusing on neurodegenerative…
DetailsMembers of the EPAD team attended the Alzheimer’s Association International Conference (AAIC) held on 14-18 July. They travelled to Los Angeles (US) from across Europe for the biggest event in dementia research. The event featured a number of key symposia, focused topic sessions and poster presentations and highlighted significant progress, results and theories that will help…
DetailsWhat is your current role in EPAD? Within the Geneva University, I act as a project manager for both EPAD and the AMYPAD Prognostic Natural History Study (PNHS). This includes all the tasks incumbent to this function, ranging from the submissions to the Ethics committee, the follow up of the speed of recruitment, the identification of some deviations…
Details
